Pharmalive - The Pulse of the Pharmaceutical Industry
Search Criteria: Search In:  
Conferences


R&D Directions Insider

Benlysta nod should benefit remaining lupus prospects

Thursday, March 10th, 2011

FDA's approval of Benlysta is indeed an historic moment for lupus patients, a community that has waited 50 years for a new treatment. The milestone, however, may have even bigger ramifications going forward. The door for additional – and perhaps more effective – new drugs for the autoimmune disorder has suddenly ...

Posted in antibodies, clinical trials, drug discovery | No Comments »

Autoimmune breakthrough evades resistance issue

Thursday, April 8th, 2010

Although commercially successful, Remicade, Humira, and Enbrel have many limitations due to allergies or infections. Their high immunogenicity, their loss of effectiveness over time, and their expense (typically costing $15,000 to $20,000 per patient per year) make these monoclonal antibodies less than ideal treatments. French biotechnology company, Neovacs SA is ...

Posted in clinical trials | 1 Comment »

Lupus drought: 50 years and counting

Thursday, October 8th, 2009

In this month’s issue of R&D Directions, we examine the 10 most active areas of therapeutic research, and also highlight some promising therapies for diseases in these categories. One condition researchers are particularly hesitant to lump into that “promising” group is lupus – and who could blame them? There have ...

Posted in Uncategorized, antibodies, clinical trials | 1 Comment »

   
about us | advertise | contact us | home
terms of use | privacy | copyright | site map 		©2012 UBM Canon